Claims for Patent: 10,391,166

Summary for Patent: 10,391,166

Title:	Short oligonucleotides as vaccine adjuvants and therapeutic agents
Abstract:	The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human). The compounds of the invention include, for example, di-, and trinucleotide compounds as provided herein. The compounds of the invention are useful for different therapeutic applications including, such as, prophylactics and therapeutics. The invention also provides design and synthesis of a compound that is useful for various therapeutic applications as mentioned herein.
Inventor(s):	Iyer; Radhakrishnan P. (Shrewsbury, MA)
Assignee:	SPRING BREAK PHARMACEUTICALS, INC. (Milford, MA)
Application Number:	14/767,113
Patent Claims:	1. A method of improving an immune system response in a subject against a tuberculosis infection, said method comprising administering to the subject a BCG vaccine; and administering to the subject an effective amount of a vaccine adjuvant of formula (II): ##STR00017## or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof, wherein X is absent, O, NH, NR, or S; X.sub.1 absent, O, or NH; A is absent, aryl, or aralkyl; n is 0, 1, 2, 3, 4, or 5; R is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, aralkyl, heterocyclic, O-alkyl, O-heteroaryl, or steroidal; R.sub.1 and R.sub.2 are each independently, H, OH, O-alkyl, alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, aralkyl, heterocyclic, O-aryl, O-heteroarylaryl, or heterocyclic; R.sub.3 is selected from H, alkyl, substituted alkyl, C(O)-alkyl, C(O)O-alkyl, C(O)-aryl, C(O)O-aryl, C(O)NH-alkyl, and C(O)NH-aryl; Y and Z are each independently O or S; B.sub.1 and B.sub.2 are each independently adenine, guanine, thymine, cytosine, uracil, or a modified nucleoside; m is 1, 2, 3, 4, 5, or 6; R.sub.4 is independently H, alkyl, substituted alkyl, C(O)-alkyl, C(O)O-alkyl, C(O)-aryl, C(O)O-aryl, C(O)NH-alkyl, C(O)NH-aryl, or a monophosphate, diphosphate, or triphosphate group. 2. The method of claim 1, wherein said vaccine adjuvant is a compound of the following structure: ##STR00018## or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof.

Details for Patent 10,391,166

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	N/A	bcg vaccine	For Injection	103050	06/21/1989		2033-02-18